Skip to main content
. 2017 May 15;2017(5):CD011673. doi: 10.1002/14651858.CD011673.pub2

Analysis 6.5.

Analysis 6.5

Comparison 6 Targeted immunotherapy alone versus standard targeted therapies in previously treated patients with metastatic renal cell carcinoma, Outcome 5 Progression‐free survival.